e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 12

A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers

Ruijuan Liu; Xia Li; Jingyao Wei; Shuaibing Liu; Yuanyuan Chang; Jiali Zhang; Ji Zhang; Xiaojian Zhang · 2019 · Frontiers in Pharmacology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Despite its narrow therapeutic window and large inter-individual variability, cyclosporine A (CsA) is the first-line therapy following organ transplantation. Metabolized mainly by CYP3A and being a substrate of P-glycoprotein (P-gp), CsA is susceptible to drug-drug interactions. Baicalin (BG) is a drug used for adjuvant therapy of hepatitis in traditional Chinese medicine. Since its aglycone Baicalein (B) inhibits CYP3A and P-gP, co-administration might affect CsA pharmacokinetics. This study investigated the effect of BG on CsA pharmacokinetics. In a two-period study, 16 healthy volunteers re

Abstract by Ruijuan Liu; Xia Li; Jingyao Wei; Shuaibing Liu; Yuanyuan Chang; Jiali Zhang; Ji Zhang; Xiaojian Zhang, Frontiers in Pharmacology (2019) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.3389/fphar.2019.00518